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Methods to constrain peptides in a bioactive α-helical conformation for inhibition of
protein-protein interactions represent an ongoing area of investigation in chemical
biology. Recently, the first example of a reversible “stapling” methodology was
described which exploits native cysteine or homocysteine residues spaced at the
i and i + 4 positions in a peptide sequence together with the thiol selective reactivity
of dibromomaleimides (a previous study). This manuscript reports on the optimization
of the maleimide based constraint, focusing on the kinetics of macrocyclization and
the extent to which helicity is promoted with different thiol containing amino acids.
The study identified an optimal stapling combination of X1 = L-Cys and X5 = L-hCys
in the context of the model peptide Ac-X1AAAX5-NH2, which should prove useful in
implementing the dibromomaleimide stapling strategy in peptidomimetic ligand
discovery programmes.
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1 | INTRODUCTION
The development of methodology to constrain peptides in a bioactive
conformation for the purposes of inhibiting protein-protein interac-
tions represents an area of significant effort.[1–13] Widely applied to
the pre-organization of helical epitopes and popularized as “stapling”,
the introduction of a constraint between the i and i + 4 residues
(Figure 1)—or to a lesser extent, i + 7 or i + 11 residues—in a peptide
sequence has been shown to be effective in biasing peptides towards
a helical conformation.[2,14–30] This pre-organization can lead to
improved binding potency towards target, increased (proteolytic) sta-
bility and increased cell permeability.[1,3,31–36] Despite this progress,
there remains a need to develop new synthetic methodology for con-
straining peptides that is readily implemented by non-specialists,
and which can be applied without recourse to sequences bearing
specialized amino acids. Key factors that determine the effectiveness
with which introduction of a constraint biases the peptide conforma-
tion towards an α-helix include: the length and rigidity of tether
between the covalently linked amino acids; the amino acid stereo-
chemistry; the presence of stereogenic centres within the tether and,
steric, electrostatic or dipolar interactions between functionality in
the tether and the peptide sequence.[37–39]
Our group recently introduced the first reversible stapling
methodology,[25] which exploits native cysteine or homocysteine resi-
dues spaced at the i and i + 4 positions in a peptide sequence together
with the thiol selective reactivity of dibromomaleimides (Figure 1).[40–43]
Using N-Alkynyl-dibromomaleimides permits further functionalization
through “click” chemistry allowing the facile constraint and diversifica-
tion of readily and/or commercially available thiol containing peptides.
The widely applied hydrocarbon stapling introduced by Verdine that
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relies on intramolecular ring closing metathesis of judiciously placed S-
pentenylalanine residues served as inspiration for our original design. To
be isoatomic with the hydrocarbon constraint we used homocysteine to
generate constrained peptides of BID (a BH3 only effector member of
the BCL-2 family) and RNase S peptide to interact with (anti-apoptotic
members of) the BCL-2 family and RNase S protein (a widely studied
enzyme which cleaves RNA) respectively. Although, the homocysteine
variants were generally more effective than the cysteine variants in pro-
moting a helical conformation and conferring enhanced affinity/ function
to either sequence, the later were also clearly tolerated. Moreover, cycli-
zation of the cysteine variants proceeded more rapidly. These observa-
tions motivated a more detailed sequence-structure analysis which we
describe in the current manuscript; we show that whilst the rate of
cyclisation is independent of the length of the constraint, the optimal
stapling combination in the context of the model peptide Ac-X1AAAX5-
NH2 employs X1 = L-Cys and X5 = L-hCys.
2 | MATERIALS AND METHODS
All reagents were purchased from either Sigma-Aldrich, Acros
Organics or Fluorochem and were used without further purification.
Solvents used for reactions and workups were purchased from Fisher
Chemical (HPLC grade). Deionized and milliQ water were obtained
from an Elga Water Purification system. All amino acids were N-Fmoc
protected and side chains were protected with; Trt (Cys, hCys); Mtt
(Lys) and OPip (Asp). The evaporation of solvents was achieved using
a Büchi R3 with a Vacubrand CVC3000 vacuum pump and condenser
connected to a recirculating cooler system Julabo F1000. LC-MS ana-
lyses were conducted on a ThermoScientific Dionex UltiMate 3000
and high-resolution mass spectrometry (HR-MS) data were recorded
using electrospray ionization in positive mode (ESI+) with a Bruker
MaXis Impact spectrometer. Preparative HPLC experiments were per-
formed using an Agilent 1260 Infinity instrument with a Jupiter
Proteo 90 Å 250 × 21.2 mm, 10 μm preparative column. Analytical
HPLC experiments were performed using an Agilent 1290 Infinity LC
series system equipped with an Ascentis Express Peptide ES-C18
100 × 2.1 mm column, 2.7 μm particle size on a 5%-50% gradient of
acetonitrile in water (with 0.1% formic acid) over 10 min.
2.1 | Solid-phase peptide synthesis
Linear pentapeptides (0.25 mmol, 1 eq) were synthesized on Rink
amide resin (loading capacity 0.81 mmol/g) using DIC and Oxyma in
DMF for amide coupling, 10% acetic anhydride in DMF for the
acetylation of the N-terminus and 20% piperidine in DMF for the
deprotection. Standard methods of coupling and deprotection sup-
plied with CEM Liberty Blue peptide synthesizer with microwave
assistance were used. After the synthesis, the resin was drained,
washed with DMF (2 × 2 mL × 2 min), DCM (2 × 2 mL × 2 minutes)
and diethyl ether (3 × 2 mL × 2 min) and dried for 1 h. Protecting
groups and the peptide were simultaneously cleaved from the resin
with TFA: H2O: TIPS: EDT (92.5:2.5:2.5:2.5; 5 mL × 3 h). The resin
was then washed with fresh TFA (2 mL × 2 min × 2). The solvent was
finally evaporated under nitrogen flux and the resulting oils were dis-
solved in dioxane: water (1:1) and freeze dried. Peptides 1a-g were
then purified using preparative HPLC. Fractions were checked using
LC-MS, and fractions containing the target peptide were concentrated
on the rotary evaporator and freeze dried.
Peptide m/z [1H]+ found m/z [1H]+ calcd. Formula
1a 479.1750 479.1747 C17H31N6O6S2
1b 479.1744 479.1747 C17H31N6O6S2
1c 479.1739 479.1747 C17H31N6O6S2
1d 479.1514 479.1747 C17H31N6O6S2
1e 493.1901 493.1903 C18H33N6O6S2
1f 493.1903 493.1898 C18H33N6O6S2
1g 507.2063 507.2054 C19H35N6O6S2
Peptide 1a (14.2 mg, 0.03 mmol, 12%), Peptide 1b (4.2 mg,
8.8 μmol, 4%), Peptide 1c (6.5 mg, 14 μmol, 5%), Peptide 1d (3.7 mg,
7.7 μmol, 3%), Peptide 1e (9.2 mg, 18 μmol, 7%), Peptide 1f (14 mg,
14%), Peptide 1g (8.5 mg, 9%); (see Supporting Information for HPLC
traces and HRMS, Figures S1 and S2).
2.2 | Preparation of constrained peptides 1-2
The syntheses of precursor crude acetylated linear peptides
(0.25 mmol, 1 eq) was carried out as described above and these were
used in the following stapling reaction without further purification.
F IGURE 1 Schematic structures for an α-helix together with
representative constraints for i to i + 4 residues; the widely employed
hydrocarbon constraint, the most effective helix inducing lactam
constraint, and the dibromomaleimide constraint explored in this
study
2 of 8 LINDSEY-CROSTHWAIT ET AL.
Peptide solutions (0.1 mmol) in a mixture of acetonitrile: 50 mM
ammonium acetate buffer pH 7.4 (1:1, 30 mL) were treated with TCEP
(32 mg, 0.11 mmol) and the reaction mixtures were stirred at room
temperature. Peptides were shown by LC-MS to be completely
reduced after 1 h. 2,3-Dibromomaleimide (28 mg, 0.11 mmol) was
then added and the reactions stirred at room temperature for a fur-
ther 1 h. After confirming the reactions were complete by LC-MS the
reaction mixtures were freeze dried. Crude peptides were dissolved in
5 mL of methanol and purified using preparative HPLC. Peptides were
purified using a flow rate of 20 mL/min and a gradient of 20-40%
methanol in water containing 0.1% TFA.
Peptide m/z [1H]+ found m/z [1H]+ calcd. Formula
2a 572.1591 572.1597 C21H30N7O8S2
2b 572.1588 572.1597 C21H30N7O8S2
2c 572.1578 572.1597 C21H30N7O8S2
2d 572.1589 572.1597 C21H30N7O8S2
2e 586.1745 586.1748 C22H32N7O8S2
2f 586.1753 586.1748 C22H32N7O8S2
2g 600.1902 600.1905 C23H34N7O8S2
Peptide 2a (14.2 mg, 25 μmol 21%), Peptide 2b (4.2 mg, 7.3 μmol,
7%), Peptide 2c (12 mg 20 μmol, 21%), Peptide 2d (6.0 mg, 10 μmol,
11%), Peptide 2e (2.2 mg, 3.7 μmol, 4%); Peptide 2f (10.8 mg,
18.4 μmol, 18%); Peptide 2g (9.9 mg, 16.5 μmol, 17%); (see Supporting
Information for HPLC traces and HRMS Figures S1 and S3).
2.3 | Synthesis of peptide 3
N-Fmoc amino acids had chains protected with Mtt (Lys); OPip (Asp).
Ac-K(Mtt)AAAD(OPip)-OH (0.1 mmol, 1 eq) was synthesized on Rink
amide resin (loading capacity 0.123 mmol/g) using DIC and Oxyma in
DMF for amide coupling, 10% acetic anhydride in DMF for the acety-
lation and 20% piperidine in DMF for the deprotection using a CEM
Liberty Blue peptide synthesizer with microwave assistance. The resin
was then drained, washed with DCM (2 × 2 mL × 2mins), and treated
repeatedly with 2% TFA in DCM (2 mL × 5 × 2 min). After washing
with DMF (2 × 2 mL, 2mins), a solution of PyBOP (4 eq) and DIPEA
(4 eq) in DMF was added to the resin and the reaction was agitated
overnight. After the synthesis, the resin was drained, washed with
DMF (2 × 2 mL × 2 min), DCM (2 × 2 mL × 2 min) and diethyl ether
(3 × 2 mL × 2 min) and dried for 1 h. Subsequently, the protecting
groups and the peptide were simultaneously cleaved from the resin
with TFA: H2O: TIPS: EDT (92.5:2.5:2.5:2.5; 5 mL × 3 h). The resin
was then washed with fresh TFA (2 mL × 2 min × 2). The solvent was
finally evaporated under nitrogen flux and the resulting oils were dis-
solved in dioxane: water (1:1) and freeze dried. The peptide was then
dissolved in acetonitrile and purified using preparative HPLC. The
peptide (7.4 mg, 15 μmol 15%), eluted at a flow rate of 20 mL/min
and a gradient of 0%-40% acetonitrile in water (with 0.1% TFA); ESI
HRMS found m/z 498.2680 [M + H]+, [C21H36N7O7]
+ requires
498.2676 (see Supporting Information for HPLC trace and HRMS Fig-
ures S1 and S3).
2.4 | UV absorbance analyses
UV absorbance analyses were recorded using a 10 mm path-length
quartz cuvette on a Cary 100 UV/VIS spectrometer. Peptide solutions
(250 μM) were prepared from aqueous peptide stock solutions (10 mM
phosphate buffer, pH 7.2) and samples were measured. Additionally,
samples were also prepared in 50% TFE/10 mM phosphate buffer
pH 7.2. The absorbance at 400 nm was recorded for peptides stapled
with maleimide, whilst the absorbance at 205 nm was recorded for the
lactam stapled peptide. The relative concentrations of the samples
could then be calculated using the Beer-Lambert law. Literature values
for the absorption coefficient of maleimide[25] and lactam[38,44] stapled
peptides were used for the calculation.
2.5 | Kinetic analyses
The kinetic mesurements were performed in 96 well-plates using a
Perkin Elmer EnVision 2103 Multilabel Reader. The 200 μL solution in
each well contained 100 μM of peptide, 100 μM of TCEP and 200 μM
of 2,3-dibromomaleimide in 50 mM phosphate buffer pH = 6. The
reactions were followed for 1 h at 20 C.
2.6 | Circular dichroism analyses
CD data were recorded using an Applied Photophysics Chirascan
Instrument and Software in a 1 mm quartz cuvette. For each scan, the
following parameters were used: 185-260 nm range at 50 nm/ min,
with a bandwidth of 1.0 nm, response time of 1 s and resolution step
width of 1 nm. Each spectrum represents the average of five scans.
The raw CD data obtained were processed by averaging the data for
five scans and subsequently subtracting the solvent signal. Next, the
CD values were converted into a relative mean residue ellipticity using
the following equation:
θ½ 215 = θ½ obs= 10*l*cð Þ n−1ð Þ
[θ]215 = observed mean residue ellipticity of a peptide at a given
wavelength; [θ]obs = measured ellipticity (mdeg); l = path length (cm);
c = molar concentration (mol dm−3); n = number of peptide resides.
Percentage helicity (fHelix) was then calculated for peptides using
the observed mean residue ellipticity of peptides at 215 nm and the
following equation




= θ½ max− θ½ 0
 
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[θ]0 = mean residue ellipticity of the peptide in random coil forma-
tion (2220-53 T); T = temperature (C); [θ]max = maximum theoretical
mean residue ellipticity for a helix of n residues, (−44 000 + [250 T])*
(1 − [x/n]) where T = temperature (C); x = empirical constant, 3;
n = number of peptide residues.
Finally, the percentage helicity was normalized relative to the per-
centage helicity of the lactam constrained peptide 3, which was taken
to have 100% α-helicity.
2.7 | X-Ray analyses
A solution of 2a (0.5 mg/mL) was dissolved in a mixture of water/
methanol (1:1) and following 2 days of slow evaporation at room tem-
perature, the constrained peptide crystallized as yellow needles. X-ray
structure determination was carried out at 120 K on an Agilent Super-
Nova diffractometer equipped with an Atlas CCD detector and con-
nected to an Oxford Cryostream low temperature device using mirror
monochromated Cu Kα radiation (λ = 1.54184 Å) from a Microfocus
X-ray source. The structure was solved by direct methods using
SHELXS[38] and refined by a full matrix least squares technique based
on F2 using SHELXL2014.[39] The compound crystallized in a triclinic
cell and was solved in the P1 space group, with one molecule and two
molecules of water in the asymmetric unit. All non-hydrogen atoms
were located in the Fourier Map and refined anisotropically. All
carbon-bound hydrogen atoms were placed in calculated positions
and refined isotropically using a “riding model.” All heteroatom bound
hydrogen atoms were located in the Fourier Map and refined iso-
tropically (see Supporting Information structure parameters Table S1).
3 | RESULTS AND DISCUSSION
We selected a pentameric alanine containing sequence as a model for
these studies. This sequence has been widely used by Fairlie and co-
workers to compare different synthetic constraints.[40] We prepared
seven different peptides 1a-g bearing different combinations of D or
L-cysteine and L-homocysteine at the i and i + 4 positions. These
could readily be reacted with dibromomaleimide to generate the con-
strained peptides 2a-g (Scheme 1 and Table 1).
To evaluate our prior qualitative observation that BID and RNase
S peptide cysteine variants were more amenable to cyclization,[25] we
first compared the rate of reaction of suitably protected amino acids
cysteine and homocysteine with dibromomaleimide. These analyses
were conducted to allow us to dissect out any differences in the reac-
tivity of the amino acid from differences in ring size for the cycliza-
tion; cysteine being anticipated to react more quickly due to the
proximal α-carbonyl. The reactions were followed by UV-vis with the
bromide for thiol substitution leading to a diagnostic spectroscopic
change allowing a qualitative analysis of the reactivity. The analyses
indicate that the cyclization proceeds significantly faster than that
observed in our original study,[25] although the greater length of the
peptide is likely to influence the accessible conformations and side-
chains of amino acids proximal to the cysteine's will differentially
affect the steric environment, and therefore, rate of cyclization, so
caution should be exercised in directly comparing this work and the
previous study. A mathematical analysis was hampered by competing
hydrolysis of the maleimide ring,[47] nonetheless the experiments indi-
cated clearly only minor differences between the two amino acids
(Figure 2A). Next the rates of cyclization of the peptides 1a-d were
assessed. These indicated no dependence of the cyclization rate on
amino acid stereochemistry, with all sequences generating near identi-
cal cyclization rates (Figure 2B). The rates of cyclization of peptides
with one or both cysteine residues replaced with homocysteine 1e-g
also showed a very small effect of the length of the created tether on
the cyclization kinetics (Figure 2C).
We then performed circular dichroism spectroscopy in phosphate
buffer and phosphate buffer with 50% trifluoroethanol (TFE). To facili-
tate comparison, we also prepared the previously reported and opti-
mally constrained sequence 3, bearing a lactam bridge between Lys1
and Asp4 as a control;[40] this lactam constraint was previously shown
to be the most effective in a comparative study of i, i + 4 constraints
leading to the maximum mean residue helicity for a five residue pep-
tide. Our CD analysis indicated that peptide 2e with X1 = L-Cys and
X5 = L-hCys to be superior to all other combinations in biasing the
conformation of the peptides towards an α-helical conformation
(Figure 3 and Table 1). We used a wavelength of 215 nm (to calculate
helicities as it has been shown that the minimum for shorter helices
shifts to lower wavelength,[48,49] and this was the value used previ-
ously for the reference control lactam bridged 3.[40] Values at 222 nm
SCHEME 1 Synthesis of constrained
pentapeptides 2a-g
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are also given, however the trends are similar. Although not as effec-
tive as the lactam bridge, relative to 3 (100% helicity in buffer and
50% TFE), 2e was observed to have helicity of 48% (buffer) and 66%
(50% TFE). None of the remaining peptides 2a-d and 2f-g exhibited
helicities more than two thirds of the values for 2e, although more
pronounced improvements on addition of TFE were observed in some
instances. Whilst the increase in helicity on addition of the helix pro-
moting solvent suggests the maleimide constraint is not fully optimal,
the lower helicity of peptides 2a-g in comparison to 3 likely reflects a
combination of this effect and the helical propensities of the thiol
containing amino acids.
We also obtained a crystal structure of peptide 2a. The conforma-
tion of the peptide in the solid state is of a “flat” extended nature
(Figure 4) with packing mediated by intermacrocycle hydrogen-
bonding and stacking of the maleimide. The structure is reminiscent
of a constrained peptide reported recently by Li and co-workers[50]
and of the cyclic peptide nanotubes described originally by Ghadiri
and co-workers.[51,52] In the context of the current study, whilst 2a
has some helical propensity (25% in buffer and 41% in TFE), solid-
state hydrogen-bonding and non-covalent interactions of the staple
highlight the complex effects on conformation that can occur through
constraining a peptide.
TABLE 1 Structures and helicities of constrained peptides
% Helicity 10 mM
sodium
phosphate at 215 nm
% Helicity 10 mM
sodium phosphate
(50% TFE) at 215 nm
% Helicity 10 mM
sodium phosphate at
222 nm
% Helicity 10 mM sodium
phosphate (50% TFE) at
222 nm
a L-Cys L-Cys 25 41 20 42
b D-Cys L-Cys 28 27 14 16
c L-Cys D-Cys 17 26 14 23
d D-Cys D-Cys 13 11 0 3
e L-Cys L-hCys 48 66 40 56
f L-hCys L-cys 11 32 6 29
g L-hCys L-hCys 13 30 9 25
3 100 100 100 100
F IGURE 2 Kinetic analyses of stapling reactions (A) reaction of amino acids Ac-L-Cys (0.32 μM) and Ac-L-hCys (0.32 μM) with
dibromomaleimide (0.16 μM) (50 mM, phosphate buffer pH 6.0), (B) reaction of 1a-d (100 μM) with dibromomaleimide and (C) reaction of 1a and
1e-g (100 μM) with dibromomaleimide (200 μM) (50 mM, phosphate buffer pH 6.0, 20C, λ = 395 nm)
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Taken together, the conformational analyses confirm that the
maleimide group is an effective bridging group to constrain peptides
in an α-helical conformation with X1 = L-Cys and X5 = L-hCys the opti-
mal combination of amino acids for maximal helicity as demonstrated
for the model pentapeptide 2e. The helical propensity of the amino
acids themselves influences the helicity as does the constraint itself
although both helix promoting properties and the non-covalent
behaviour of the staple should be considered. Similarly, the influence
of proximal amino acids to the constraint should be considered; whilst
these studies have been performed on a model pentapeptide, the con-
straint should serve simply to nucleate the helical conformation,
hence steric and non-covalent interaction with amino acids found
inside the constrained sequence or distal to it, together with the
length over which the nucleation site is required to propagate, should
be considered.
4 | CONCLUSIONS
In summary we have performed a comparative analysis on the
α-helix inducing properties of maleimide constraints in i to i + 4
bridged thiol containing pentapeptides. The study established that
the rate of cyclisation is independent of the length of the con-
straint, indicating the size of the macrocycle is such that entropic
F IGURE 3 Circular Dichroism analyses of peptides 2a-g and 3 (A) peptide concentration 250 μM (10 mM phosphate buffer, pH 7.2, 298 K),
(B) peptide concentration 250 μM (50% TFE, 10 mM phosphate buffer and pH 7.2, 298 K)
F IGURE 4 X-ray structure analyses of peptide 2a, (A) the peptide adopts a “flat” extended conformation in which there are no intramolecular
hydrogen-bonds and (B) packing of the peptide is mediated by intermacrocycle hydrogen-bonding interactions, water-mediated intermacrocycle
hydrogen-bonding and stacking of the maleimide unit
6 of 8 LINDSEY-CROSTHWAIT ET AL.
disorder dominates the ring closure reaction. Most significantly
we identified an optimal stapling combination of X1 = L-Cys and
X5 = L-hCys in the context of the model peptide Ac-X1AAAX5-
NH2 and highlighted the ability of non-covalent behaviour of
the constraint to influence conformation. These studies should
inform more effective use of maleimide based stapling reagents in
future studies.
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